Cellectar Biosciences (CLRB) Shares Outstanding (2010 - 2026)
Cellectar Biosciences (CLRB) posted Shares Outstanding (Entity) of $2.6 million for Q4 2025, down 18.29% sequentially from $3.2 million in Q3 2025, and up 113.69% YoY from $1.2 million in Q4 2024.
Cellectar Biosciences (CLRB) Shares Outstanding (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Shares Outstanding (Entity) for 16 years, with the latest figure at $2.6 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 113.69% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (up 113.69% YoY) and the FY2025 annual result came in at $2.6 million, up 113.69% from the prior year.
- Shares Outstanding (Entity) eased to $2.6 million in Q4 2025 per CLRB's latest filing, from $3.2 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $3.2 million in Q3 2025 and troughed at $175737.0 in Q1 2021.
- A 5-year average of $851087.8 and a median of $327615.5 in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2021 and 2022: Shares Outstanding (Entity) jumped 461.16% in 2021, then fell 0.0% in 2022.
- Over 5 years, Shares Outstanding (Entity) stood at $203651.0 in 2021, then gained by 15.47% to $235165.0 in 2022, then surged by 73.22% to $407345.0 in 2023, then soared by 199.65% to $1.2 million in 2024, then soared by 113.69% to $2.6 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $2.6 million, $3.2 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 3.16 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 978,125.00 |
| Dec 31, 2023 | 407,345.00 |
| Sep 30, 2023 | 376,920.00 |
| Jun 30, 2023 | 375,336.00 |
| Mar 31, 2023 | 375,336.00 |
| Dec 31, 2022 | 235,165.00 |
| Sep 30, 2022 | 203,650.00 |
| Jun 30, 2022 | 203,650.00 |
| Mar 31, 2022 | 203,651.00 |
| Dec 31, 2021 | 185,034.00 |
| Sep 30, 2021 | 199,541.00 |
| Jun 30, 2021 | 175,862.00 |